Optimizing Enrollment Cycle Time
In a recently published article, PhESi detailed how we utilized our industry-leading innovative clincial
trial planning platform to provide optimized guidance on clinical trial operative deliverables
for one of our clients. The subject trial is a randomized phase 3 hematology clinical trial, largest to this date.
We were able to accurately forecast the enrollment cycle time for the first time the industry. To learn more about how
PhESi achieved it, please read this article
Jonathan Peachey Joins PhESi as Head of Client Services
PhESi has announced the appointment of Jonathan Peachey as a member of the Board and Head of Client Services today.
Peachey has an outstanding track record of growing successful businesses in the life sciences industry, most recently as a Board Director and Head of Client Partnerships at Kinapse Ltd. Peachey has 25 years of industry experience, leading and delivering business transformation across Pharma R&D. His capabilities span strategy, business and IT transformation and performance improvement. Previously, Peachey has led IBM's EU Pharma R&D consulting practice and has held roles at GSK, BMS and Pfizer.
Breakthrough in Forecasting Enrollment Rate
In a recently published article titled
Forecasting Enrollment Rate in Clinical Trials in APPLIED CLINICAL TRIALS online, Gen Li,
President of PhESi, revealed that clinical trial enrollment rates can be expressed by simple mathematical formulas.
For the first time, we can accurately forecast enrollment rate in clinical trials, and shorten
enrollment cycle time through proactively designed actions.